EP4739778A2 - Rna-molekül - Google Patents

Rna-molekül

Info

Publication number
EP4739778A2
EP4739778A2 EP24743461.6A EP24743461A EP4739778A2 EP 4739778 A2 EP4739778 A2 EP 4739778A2 EP 24743461 A EP24743461 A EP 24743461A EP 4739778 A2 EP4739778 A2 EP 4739778A2
Authority
EP
European Patent Office
Prior art keywords
lna
rna
locked
nucleotide
rna molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24743461.6A
Other languages
English (en)
French (fr)
Inventor
Robin Shattock
Laia NOGAREDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Publication of EP4739778A2 publication Critical patent/EP4739778A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP24743461.6A 2023-07-06 2024-07-05 Rna-molekül Pending EP4739778A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB202310390 2023-07-06
PCT/GB2024/051765 WO2025008641A2 (en) 2023-07-06 2024-07-05 Rna molecule

Publications (1)

Publication Number Publication Date
EP4739778A2 true EP4739778A2 (de) 2026-05-13

Family

ID=91953781

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24743461.6A Pending EP4739778A2 (de) 2023-07-06 2024-07-05 Rna-molekül

Country Status (2)

Country Link
EP (1) EP4739778A2 (de)
WO (1) WO2025008641A2 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045518B2 (en) * 2002-11-18 2015-06-02 Santaris Pharma A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
CN104685056A (zh) * 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
CN105188715B (zh) * 2013-03-15 2018-12-25 米拉根医疗股份有限公司 Mir-145的锁定核酸抑制剂及其用途
GB201908729D0 (en) 2019-06-18 2019-07-31 Imp College Innovations Ltd RNA construct

Also Published As

Publication number Publication date
WO2025008641A3 (en) 2025-03-13
WO2025008641A2 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
JP7089003B2 (ja) Ｒｎａの免疫原性を低減するための方法
EP3332019B1 (de) Verfahren zur in-vivo-produktion von rna in einer wirtszelle
EP3445850B1 (de) Verfahren zur bereitstellung von einzelsträngiger rna
EP3134131B1 (de) Nukleinsäureimpfstoffe
EP3935162A1 (de) Zirkuläre polyribonukleotide und pharmazeutische zusammensetzungen davon
CA3150163A1 (en) Immuno oncology combination therapies with il-2 conjugates
BR112020002272A2 (pt) conjugados de citocina para o tratamento de doenças autoimunes
US20170136129A1 (en) Stabilised Formulations of RNA
AU2011358150A1 (en) Pharmaceutical composition consisting of RNA having alkali metal as counter ion and formulated with dications
CN119654141A (zh) 脂质纳米颗粒的组合物
US20220307017A1 (en) Minimal Messenger RNAs and uses thereof
WO2023166314A2 (en) Rna molecule
WO2025008641A2 (en) Rna molecule
WO2025052108A2 (en) Rna molecule
CN122060818A (en) Chemically modified circular RNA molecules, methods of making and uses thereof
WO2025253381A1 (en) Cyclic gmp-amp synthase variants and use thereof
Nakanishi et al. mRNA Medicines and mRNA Vaccines
WO2026103936A1 (zh) 化学修饰的环状rna分子及其制备方法和用途
WO2025017029A1 (en) Non-natural building blocks for enhanced translation and stability of mrna
HK40072892B (en) Nucleic acid vaccines
HK40075781A (en) Methods for providing single-stranded rna
HK1261163B (en) Methods for providing single-stranded rna
NZ786562A (en) Methods for providing single-stranded RNA
HK1235003B (en) Nucleic acid vaccines

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR